From GlobeNewswire: 2025-03-10 06:55:00

BioNTech has a robust oncology pipeline with over 20 active Phase 2 and Phase 3 clinical trials, focusing on immunomodulator candidate BNT327 and mRNA cancer immunotherapies. The company completed the acquisition of Biotheus and maintains global market leadership with COVID-19 vaccines. Financially, revenues for Q4 2024 were €1.2 billion, with a full year net loss of €0.7 billion. Cash and cash equivalents are at €17.4 billion. Expectations for 2025 revenues are between €1.7 billion and €2.2 billion. A conference call and webcast are scheduled for March 10, 2025, to discuss these results and updates.

BioNTech’s CEO, Prof. Ugur Sahin, highlighted the company’s progress in advancing its oncology pipeline, with multiple data readouts expected in 2025 and 2026. The company aims to become a diversified multi-product oncology portfolio company by 2030. Financially, revenues for Q4 2024 were €1.2 billion, with a net loss of €0.7 billion for the full year. Cash and cash equivalents stand at €17.4 billion as of December 31, 2024. Expectations for 2025 revenues are between €1.7 billion and €2.2 billion.

BioNTech reported financial results for Q4 and full year 2024, with revenues of €1.2 billion for Q4 and €2.8 billion for the full year. The net loss for the full year was €0.7 billion, with diluted loss per share of €2.77. Cash and cash equivalents, including security investments, totaled €17.4 billion as of December 31, 2024. The company expects 2025 revenues between €1.7 billion and €2.2 billion.

BioNTech made progress in its oncology pipeline with key programs like BNT327 and mRNA cancer immunotherapies. The company initiated global Phase 3 clinical trials for BNT327 and presented promising data at the San Antonio Breast Cancer Symposium. Additional clinical trials and data readouts are planned for 2025. Financially, the company reported revenues of €1.2 billion for Q4 2024 and a net loss of €0.7 billion for the full year. Cash and cash equivalents totaled €17.4 billion as of December 31, 2024.



Read more at GlobeNewswire:: BioNTech Announces Fourth Quarter and Full Year 2024